Berkovitch L

Department of Psychiatry, Yale University School of Medicine; New Haven, CT, USA; Institute de Neuromodulation, GHU Paris, Psychiatrie et Neurosciences, Centre Hospitalier Sainte-Anne, Pôle Hospitalo-universitaire 15, Université Paris Cité; Paris, France; Unicog, Saclay CEA Centre, Neurospin; Gif-Sur-Yvette Cedex, France.

2 preprints · 6 papers · ORCID

PreprintKetamine

Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression

Muh C, Favre P, Lutkenherm IK +3

Europe PMC2026
ArticleKetamine

Ketamine Alters Tuning of Neural and Behavioral Spatial Working Memory Precision.

Rahmati M, Moujaes F, Suljic NP +22

Europe PMC2026
ArticlePsilocybin

Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.

Mallevays M, Berkovitch L

Europe PMC2026
PreprintKetamine

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

Mallevays M, Fuet L, Danon M +15

Europe PMC2026
ArticleKetamine

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

Rothärmel M, Mekaoui L, Kazour F +21

Europe PMC2026
ArticleKetamine

Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?

Danon M, Ostronoff G, Petit AC +5

Europe PMC2026
ArticlePsilocybin

Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.

Berkovitch L, Fauvel B, Preller KH +1

Europe PMC2025
ArticlePsilocybin

[Efficacy of psychedelics in psychiatry, a systematic review of the literature].

Berkovitch L, Roméo B, Karila L +2

Europe PMC2021